Caris Life Sciences, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Caris reported Q3 2026 revenue of $275.4M (+27% YoY) driven by 61,500 clinical cases and 358,000 total oncology tests. The company raised full-year 2026 revenue guidance to $1.04–$1.05B (from prior guidance), representing 28–29% growth. However, net income fell 37% to $15.3M (from $24.3M YoY), operating expenses rose 42% to $163.0M, and free cash flow turned negative at $(39.7)M despite positive Adjusted EBITDA of $44.4M.
Why this rating
Raised guidance and strong volume growth (+21%) offset by margin compression, expense acceleration, and cash flow deterioration. Meaningful for $3.9B company but execution risks emerging.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.